Ocular manifestations of Sturge–Weber syndrome: pathogenesis, diagnosis, and management

Flavio Mantelli¹
Alice Bruscolini²
Maurizio La Cava²
Solmaz Abdolrahimzadeh²
Alessandro Lambiase²

¹Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, USA; ²Department of Sense Organs, Section of Ophthalmology, University of Rome "Sapienza", Rome, Italy

Abstract: Sturge–Weber syndrome has been included in the group of phakomatoses that is characterized by hamartomas involving the brain, skin, and eyes. The characteristic facial port-wine stain, involving the first branch of the trigeminal nerve and the embryonic vasculature distribution in this area, leads to several ocular complications of the anterior segment and can involve the eyelids and conjunctiva. The posterior segment of the eyes is also affected with diffuse choroidal hemangiomas. However, the most frequent ocular comorbidity is glaucoma with a prevalence rate ranging from 30%–70%. Glaucoma is related to anterior chamber malformations, high episcleral venous pressure (EVP), and changes in ocular hemodynamics. Glaucoma can be diagnosed at birth, but the disease can also develop during childhood and in adults. The management of glaucoma in Sturge–Weber syndrome patients is particularly challenging because of early onset, frequently associated severe visual field impairment at the time of diagnosis, and unresponsiveness to standard treatment. Several surgical approaches have been proposed, but long-term prognosis for both intraocular pressure control and visual function remains unsatisfactory in these patients. Choroidal hemangiomas may also lead to visual impairment through exudative retinal detachment and macular edema. Treatment of exudative hemangioma complications is aimed at destructing the tumor or decreasing tumor leakage.

Keywords: Sturge–Weber syndrome, glaucoma, choroidal hemangiomas, port-wine stain, congenital disease, glaucoma surgery

Introduction

Sturge–Weber syndrome (SWS) has been included in the group of phakomatoses that includes neurofibromatosis, Klippel–Trenaunay syndrome, tuberous sclerosis, and von Hippel–Lindau syndrome.¹ SWS, also known as encephalotrigeminal angiomatosis, is a condition that includes leptomeningeal hemangioma, facial angiomatosis or nevus flammeus (also called port-wine stain [PWS]), and ocular pathological changes.²⁻⁵ The incidence of SWS is ~1:50,000 infants, with no significant difference between males and females.⁶ No hereditary pattern or predisposition has been shown, and no malignant transformation has been demonstrated.⁷⁻⁸ Several genes in the 17p1-p13 region, which are known to be involved in SWS, are also known to be linked to rare abnormalities and syndromes, such as retinitis pigmentosa, cerebral astrocytoma, subglottic stenosis, Klippel–Trenaunay–Weber syndrome, and phakomatosis pigmentovascularis.⁹⁻¹³

The embryologic basis of SWS has been reported to be related to an impaired development of the cell precursors in the neural crest during the first embryological trimester, leading to the characteristic malformations observed in the central nervous system, skin, and eyes.¹ Happle suggested that somatic mosaic mutations involving the skin cause sporadic or scattered birth defects, and the phase of embryonic development during which this occurs is fundamental.¹⁴ Shirley et al recently published a
ground-breaking study where a mutation in the GNAQ gene was identified, which leads to stimulation of cell proliferation and inhibition of apoptosis. The authors found that the mutation is associated with both sporadic PWSs and SWS.

Diagnosis is easily performed when the classical clinical signs of SWS are present, consisting of unilateral facial PWS along the first branch of the trigeminal nerve, hemiatrophy, progressive seizures, contralateral hemiparesis, mental deficiencies, hemianopia, and ipsilateral glaucoma. However, Waclchi et al showed that the PWS distribution may in fact follow the embryonic vasculature distribution of the face, rather than the trigeminal nerve. Neuroimaging techniques help to perform the diagnosis, showing gyriform calcifications that engage the parietal and occipital lobes, leptomeningeal angiomatosis, and astrogliosis in the brain. The diagnosis of SWS is based on the presence of at least two of the three manifestations of the classic triad (leptomeningeal angioma, PWS, and ocular abnormalities). However, clinical findings of SWS may vary, showing variable neural signs and symptoms with the absence of or varying ocular involvement.

According to the clinical manifestation, SWS is classified into four types: 1) presence of brain and facial angioma, with or without glaucoma, 2) PWS without brain involvement, with or without glaucoma, 3) isolated brain angioma, usually without glaucoma, and 4) type 1 associated with systemic manifestation such as tuberous sclerosis (Table 1).

### Ocular findings

Approximately 50% of SWS patients show pathologic ocular changes, usually ipsilateral to the PWS, involving the eyelid, anterior chamber, cornea, choroid, and retina. The presence of PWS may involve the eyelid and trigger pathological alterations in the ocular blood flow. The bulbar conjunctiva (frequently at the limbus) may show diffused or localized area of pinkish discoloration related to increased conjunctival vascularization. Episceral vessel dilatation can be observed in approximately half of SWS patients.

Several anterior chamber changes have been described in SWS including vascular formations in the trabecular meshwork near the scleral spur surrounded by large homogeneous extracellular matrix, association of the endothelial layer lining of Schlemm’s canal with the basal lamina, and presence of several villi and giant vacuoles within the endothelial cells that appear as transcellular channels.

These anatomical alterations justify the frequent development of glaucoma in 30%–70% of SWS patients. Glaucoma in SWS patients shows a bimodal peak of age development: an early-onset (congenital) form affecting ~60% of patients and a later-onset form during childhood and adolescence (~40% of cases). Glaucoma in SWS is unilateral and is associated with the presence of an ipsilateral PWS, which most frequently involves both the eyelids (72%) and sometimes only the upper eyelid (21%). The most frequent form of glaucoma in SWS patients is open-angle glaucoma leading to progressive visual field loss. However, acute glaucoma attack due to chamber angle closure has also been described. Congenital glaucoma is frequently associated with corneal changes (25%), including haze, megalocornea, and buphthalmos. Other anterior segment alterations have been described in SWS patients including iris heterochromia and cataract.

The posterior segment of the eye is also involved with hemangiomas of the choroid (20%–70% of cases). Choroidal hemangiomas can be clinically divided into localized and diffuse forms, but it is the diffuse form that typically occurs in SWS patients. Clinically, ophthalmoscopy shows a bright red or red–orange color appearance of the fundus, related to the increase of well-formed choroidal vessels, while hemangiomas appear as diffuse or localized areas with a dark red color and a “tomato ketchup” appearance. The presence of choroidal hemangiomas is frequently asymptomatic; however, the choroid may become significantly thickened, and an increased risk of glaucoma development has been reported in patients with choroidal hemangioma.

Alteration of the choroidal vessels may lead to severe retinal complications and potentially to visual loss. Subretinal hemorrhage, retinal degeneration, retinal serous detachment, photoreceptor degeneration, cystoid macular edema, macular serous detachment, tortuous retinal vessels, and optic disc coloboma have been described in SWS patients.

### Ophthalmic management

Routine slit lamp examination is sufficient to detect most of the alterations typically observed in SWS patients; however, if young children cannot cooperate and there is concern for visually threatening diseases such as glaucoma, examination under general anesthesia may be required. Anterior segment alterations include eyelids, conjunctival and episcleral hemangiomas, and corneal changes related to congenital glaucoma. Fundus examination by indirect ophthalmoscopy

<table>
<thead>
<tr>
<th>Table 1 Classification of Sturge–Weber syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>Type I</td>
</tr>
<tr>
<td>Type II</td>
</tr>
<tr>
<td>Type III</td>
</tr>
<tr>
<td>Type IV</td>
</tr>
</tbody>
</table>

Notes: +, Present; –, absent; ±, feature can be observed but is not ubiquitous.
Several new hypotheses and factors have been formulated on glaucoma pathogenesis. Several hypotheses and factors have been formulated to explain the pathogenic mechanisms leading to the development of glaucoma associated with rare conditions.

The main theories on the pathogenesis of glaucoma in SWS include the following:

1) A mechanical mechanism related to congenital malformation of the anterior chamber angle leading to increased resistance to aqueous humor outflow: in this case, the iris can also not have the flat anterior insertion characteristic of the congenital form;

2) an increase in episcleral venous pressure (EVP) due to arteriovenous shunts into the episcleral hemangioma; this theory is based on the observation of a normal angle structure, blood within Schlemm’s canal, and more severe glaucoma;

3) fluid hypersecretion by either the ciliary body or the choroidal hemangioma; and

4) abnormal hemodynamics of the episclera and the anterior chamber angle due to premature aging of the trabecular meshwork–Schlemm’s canal complex, as observed in SWS later-onset glaucoma.

In SWS patients, an increase in EVP, as compared to normal eyes, has been reported in glaucoma-affected eyes. However, no significant difference in EVP was observed between glaucoma-affected and normal eyes in SWS patients, suggesting that elevated EVP is only a risk factor for glaucoma onset. Retrobulbar blood flow was also impaired in SWS patients, suggesting an increased risk to develop glaucoma with aging. However, no significant difference in the arterial retrobulbar blood flow was observed between the glaucomatous and the normal fellow normal.

Glaucoma pathogenesis in SWS patients is complex, including different interlinked mechanisms that change their role with aging. Indeed, in congenital and early-onset glaucoma forms, angle malformations play a crucial role. In late-onset glaucoma, an increase in EVP, probably related to progressive hypertrophy and dilatation of the episcleral veins as reported for PWS, has a major pathogenic role.

A few cases of acute glaucoma attack due to angle closure have been described in SWS. Maruyama et al reported a case of a patient with SWS who developed acute glaucoma associated with posterior scleritis, edema of the ciliary body, ciliochoroidal effusion, and anterior rotation of the ciliary body. In this case, it was hypothesized that the ciliary body effusion induced angle closure by moving the iridolenticular diaphragm forward, which led to acute glaucoma attack. This mechanism of glaucoma induction has also been described following the use of the drug topiramate, which is used for seizures that can occur in SWS patients with leptomeningeval involvement.
described as related to pupil block with or without ectopia lentis and pigment dispersion.\textsuperscript{51,52} In these cases, ultrasound biomicroscopy may represent a precious tool to identify and characterize the pathogenic mechanism of acute glaucoma attack.\textsuperscript{53}

**Medical treatment of glaucoma**

The main goal of glaucoma treatment is to control IOP and to avoid progressive optic nerve damage and visual field loss. Both medical and surgical approaches have been performed to halt glaucoma progression in SWS patients (Table 2). Due to the rare nature of the disease, only small case series have been published leading to a relatively low level of evidence regarding treatment efficacy. Topical antiglaucoma drugs seem to be less efficacious in SWS patients with congenital glaucoma, while they represent first-line therapy for patients with late-onset glaucoma.\textsuperscript{44}

Ong et al showed that latanoprost eye drops, as adjunctive therapy, were effective in controlling glaucoma in 50% of 14 patients with SWS at 1 year of follow-up.\textsuperscript{54} In line with this, Yang et al demonstrated that latanoprost treatment induced a significant pressure decrease in 33% (two eyes) of SWS glaucoma patients.\textsuperscript{55} Latanoprost acts by increasing uveoscleral outflow, theoretically bypassing the obstacle to the passage of aqueous humor due to the increase in EVP. However, long-term use of prostaglandins in SWS patients should be carefully evaluated since one of the potential side effects of these drugs is uveal effusion.

Only a few case reports describe the use of other antiglaucoma drugs in patients with SWS, suggesting that treatment with beta-blockers and carbonic anhydrase inhibitors is effective in the absence of buphthalmos.\textsuperscript{56}

Wygnanski-Jaffe et al used oral propanolol for treating glaucoma in SWS patients.\textsuperscript{57} Systemic propranolol is effective in inducing reduction of hemangiomas of the skin, orbit, larynx, and eyes.\textsuperscript{58,59} However, systemic propranolol was ineffective in three of four children with SWS-related glaucoma.\textsuperscript{57}

A hypothesis to justify the low efficacy of antiglaucoma drugs in controlling SWS-related glaucoma is that most of these drugs do not affect EVP, highlighting the need for novel antiglaucoma medications specifically targeting EVP.

### Table 2 Treatment of Sturge–Weber syndrome-associated glaucoma

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Number of patients</th>
<th>Type of study</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basler and Sowka\textsuperscript{64}</td>
<td>2011</td>
<td>1</td>
<td>Case report</td>
<td>Travoprost eye drop</td>
<td>Good IOP control</td>
</tr>
<tr>
<td>Sharan et al \textsuperscript{65}</td>
<td>2009</td>
<td>24</td>
<td>Retrospective</td>
<td>Medical/surgery</td>
<td>Good IOP control: 9 mono- and 9 multi-drug therapy; 10 trabeculectomy and 2 valve implant</td>
</tr>
<tr>
<td>Ong et al\textsuperscript{10}</td>
<td>2003</td>
<td>14</td>
<td>Retrospective</td>
<td>Latanoprost eye drop</td>
<td>Good IOP control in 50% at 1 year</td>
</tr>
<tr>
<td>Yang et al\textsuperscript{10}</td>
<td>1998</td>
<td>6</td>
<td>Prospective</td>
<td>Latanoprost eye drop</td>
<td>Good IOP control in 33%</td>
</tr>
<tr>
<td>Wygnanski-Jaffe et al\textsuperscript{70}</td>
<td>2015</td>
<td>4</td>
<td>Prospective</td>
<td>Oral propranolol</td>
<td>Not effective as single treatment: 75% required additional treatment</td>
</tr>
<tr>
<td>Saltzmann et al\textsuperscript{80}</td>
<td>2012</td>
<td>7</td>
<td>Retrospective</td>
<td>Trabeculectomy–trabeculectomy</td>
<td>Not effective and high failure rate</td>
</tr>
<tr>
<td>Board and Shields\textsuperscript{62}</td>
<td>1981</td>
<td>5</td>
<td>Case series</td>
<td>Trabeculectomy</td>
<td>Good IOP control in 20% at 6 months</td>
</tr>
<tr>
<td>Agarwal et al\textsuperscript{62}</td>
<td>1993</td>
<td>16</td>
<td>Retrospective</td>
<td>Trabeculectomy–trabeculectomy</td>
<td>Good IOP control in 61% at 42 months</td>
</tr>
<tr>
<td>Mandal\textsuperscript{65}</td>
<td>1999</td>
<td>9</td>
<td>Case series</td>
<td>Trabeculectomy–trabeculectomy</td>
<td>Good IOP control in all patients at 1 year</td>
</tr>
<tr>
<td>Audren et al\textsuperscript{41}</td>
<td>2006</td>
<td>6</td>
<td>Retrospective</td>
<td>Deep sclerectomy</td>
<td>Not effective at 26 months</td>
</tr>
<tr>
<td>Hamush et al\textsuperscript{41}</td>
<td>1999</td>
<td>10</td>
<td>Case series</td>
<td>Ahmed valve</td>
<td>Good IOP control in 30% at 60 months</td>
</tr>
<tr>
<td>Amini et al\textsuperscript{70}</td>
<td>2007</td>
<td>7</td>
<td>Prospective</td>
<td>Molteno tube</td>
<td>Good IOP control in 43% at 36 months</td>
</tr>
<tr>
<td>Naranjo-Bonilla et al\textsuperscript{71}</td>
<td>2014</td>
<td>1</td>
<td>Case report</td>
<td>Ex-Press® implant</td>
<td>Good IOP control at 10 months</td>
</tr>
<tr>
<td>Elgin et al\textsuperscript{72}</td>
<td>2007</td>
<td>1</td>
<td>Case report</td>
<td>Ex-Press® implant</td>
<td>Good IOP control with adjunctive trabeculectomy</td>
</tr>
<tr>
<td>Van Emelen et al\textsuperscript{73}</td>
<td>2000</td>
<td>8</td>
<td>Retrospective</td>
<td>Medical/surgery</td>
<td>Good IOP control in 12% with medical therapy alone</td>
</tr>
</tbody>
</table>

**Abbreviation:** IOP, intraocular pressure.
patients with SWS. These authors suggested to consider alternative surgical procedures and closer postoperative monitoring due to this significant relative risk of failure. One of the possible explanations of surgery failures in SWS children is that goniosurgery does not affect EVP, suggesting that pathogenic mechanisms other than the simple angle malformation influence glaucoma progression.

Other surgical approaches include filtering procedures such as trabeculectomy, posterior lip sclerotomy, and trabeculectomy–trabeculotomy, which bypass the altered trabecular meshwork–Schlemm’s canal complex, creating an alternative outflow passage for the aqueous humor, independent to the distal episcleral veins. However, filtering procedures have been associated with severe complications such as expulsive choroidal hemorrhage, bleeding, prolonged flat anterior chamber, and high risk of bleb failure. Intraoperative use of antimitic agents such as mitomycin does not improve the outcome. Therefore, combined procedures such as trabeculotomy–trabeculectomy have been suggested as the first-line approach in infants and children.

Alternative surgical procedures include nonpenetrating sclerectomy, valve drainage implants, and ciliodestructive procedures in adults. Nonpenetrating sclerectomy has been shown to have an efficacy similar to trabeculectomy in controlling SWS-related glaucoma, with a lower rate of complications. However, in SWS patients, the presence of episcleral hemangioma and angle malformations make this procedure extremely difficult and increase the rate of failure.

Valve implant is also a successful method for IOP management. In SWS, the Ahmed-type valve was shown to induce long-term decrease of IOP by improving aqueous humor outflow. On the other hand, the use of the Molteno tube showed an unfavorable outcome due to an elevated complication rate in children with SWS.

Two studies reported that Ex-Press valve was successfully implanted in children with SWS as an elective surgical procedure, and in the other case, 10 days prior to performing trabeculectomy. On the other hand, the use of the Ex-Press glaucoma implant in another child with SWS was complicated by choroidal detachment, which resolved with medical therapy. Lastly, it is worth mentioning that cyclocryotherapy has been used successfully in patients with SWS and buphthalmos in combination with topical antiglaucoma therapy or trabeculectomy. Nevertheless, cyclocryotherapy can be burdened by severe complications such as hypotony and phthisis bulbi. Unfortunately, sometimes, even with medical and/or surgical treatment glaucoma leads to severe visual field damage, visual acuity loss, and optic nerve atrophy; only rehabilitation methods can help in improving the quality of life of these patients.

### Treatment of other ocular manifestations

Facial PWSs can be successfully treated by laser. Better esthetic results are achieved when treating the lesions localized on the central forehead rather than the lesions on the central face. To obtain better results, PWS should be treated early since there is a tendency to thickening and nodular transformation with aging.

Laser treatment should be superficial in order to avoid potential complications related to a decrease of brain venous outflow through PWS vessels, potentially leading to cerebral venous deterioration, choroidal vessel dilatation, retinal exudative detachment, and increase in IOP. Therefore, deep photoagulation and debulking surgery should be avoided in the treatment of PWS.

As previously described, visual loss in SWS patients is mainly related to glaucoma development, but choroidal hemangiomas may also lead to visual impairment thorough exudative retinal detachment and macular edema. The treatment of exudative hemangioma complications is aimed at destructing the tumor or at least at decreasing tumor leakage. Several treatments have been proposed including photocoagulation, photodynamic therapy (PDT), external beam radiotherapy, brachytherapy, and anti-vascular endothelial growth factor (VEGF). The scopes of these methods are to reduce tumor size, induce vessel atrophy, close leaking vessels, and induce inhibition of VEGF to ultimately diminish subretinal fluid, which causes increased retinal and macular thickness as observed with optical coherence tomography.

Photocoagulation causing destruction of the tumor has been considered as the most effective treatment in reducing leakage. However, several complications can be observed following intense photoagulative treatment, leading to the proposal of an alternative, less invasive laser procedure, such as grid treatment, that is safer but has a higher recurrence of subretinal fluid accumulation.

PDT is theoretically the most indicated procedure to treat choroidal hemangiomas, inducing vessel atrophy and reducing leakage. However, currently, only a few cases of diffuse choroidal hemangioma have been treated with PDT, probably due to the risk of inducing scarring and pigmentary changes of the fovea.

In case of diffuse choroidal hemangioma complicated by serous retinal detachment, an alternative treatment is external beam radiotherapy.

Clinical improvement
has been observed months following the first application but recurrence frequently occurs. Repeated applications should be carefully evaluated since they can induce several complications such as cataract, neuropathy, and radiation retinopathy. 87 Exudative retinal detachment related to choroidal hemangiomas has also been successfully treated using brachytherapy with cobalt-60 and ruthenium-106. 89–92 Intravitreal injection of pegaptanib (an anti-VEGF) has also been described in one SWS patient with exudative retinal detachment with satisfactory results. 93,94

Conclusion

Glaucoma is the most common ocular complication in SWS. The most frequent form is congenital glaucoma, but it can also occur in children and adults, making careful ophthalmic follow-up of SWS patients mandatory. Indeed, glaucoma secondary to SWS is a challenging disease due to its early development and poor response to standard medical treatment.

Surgery is frequently required to obtain long-term control of IOP in order to avoid visual function loss. However, several severe complications related to surgical procedures have been described in these patients, including choroidal effusion, expulsive hemorrhage, and exudative retinal detachment. Moreover, in SWS, the surgical success rate is the lowest among secondary glaucomas, since surgical failure, uncontrolled IOP, and low vision outcomes have been frequently reported. 45,50,61 To date, despite the wide range of available medical and surgical approaches to treat both the congenital and late-onset forms of glaucoma, the development of this ocular complication still represents the worst prognostic factor for vision loss in SWS patients.

Choroidal hemangiomas are present in 20%–70% of cases, and the choroid may become significantly thickened and can be associated with an increased risk of glaucoma development. 29 Choroidal hemangiomas may be asymptomatic; however, severe forms may lead to visual impairment thorough exudative retinal detachment and macular edema. The treatment of exudative complications is aimed at destroying the tumor or at least at decreasing tumor leakage.

Disclosure

The authors report no conflicts of interest in this work.

References

Clinical Ophthalmology 2016:10
submit your manuscript | www.dovepress.com
Dovepress
Ocular manifestations of Sturge–Weber syndrome


34. Lee J, Kong M, Kee C. Comparison of visual field progression between relatively low and high intraocular pressure groups in normal tension glaucoma patients. J Glaucoma. 2014;23:553–560.


